Abiopharma

Result of Annual General Meeting

Addex Therapeutics Reports Q1 2025 Financial Results and Provides Corporate Update

VERVE THERAPEUTICS INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Verve Therapeutics, Inc. - VERV

SAGE THERAPEUTICS INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Sage Therapeutics, Inc. - SAGE

NASDAQ symbol attribute type Financial_Status was changed. Previous value: Deficient. New value: Normal.

NASDAQ symbol attribute type Financial_Status was changed. Previous value: Deficient. New value: Normal.

NASDAQ symbol attribute type Financial_Status was changed. Previous value: Deficient. New value: Normal.

Ceasing to be a substantial holder

New Form 4 - CareCloud, Inc. Filed: 2025-06-18 AccNo: 0001641172-25-015661 Size: 5 KB

New Form 4 - ARDELYX, INC. Filed: 2025-06-18 AccNo: 0001628280-25-032226 Size: 5 KB

New Form 4 - Axsome Therapeutics, Inc. Filed: 2025-06-18 AccNo: 0000950170-25-088105 Size: 18 KB

New Form 4 - Moleculin Biotech, Inc. Filed: 2025-06-18 AccNo: 0001437749-25-020803 Size: 8 KB

New Form 4 - ADMA BIOLOGICS, INC. Filed: 2025-06-18 AccNo: 0001140361-25-023017 Size: 13 KB

New Form 4 - Moleculin Biotech, Inc. Filed: 2025-06-18 AccNo: 0001437749-25-020802 Size: 8 KB

Incyte anuncia la aprobación de Monjuvi® (tafasitamab-cxix) por parte de la FDA en combinación con rituximab y lenalidomida para tratar pacientes con linfoma folicular recidivante o refractario